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Abstract
Introduction: The volume of the striatal structures has been associated with 
disease	 progression	 in	 individuals	 with	 Huntington's	 disease	 (HD)	 from	 North	
America,	Europe,	and	Australia.	However,	 it	 is	not	known	whether	the	gray	mat-
ter	 (GM)	 volume	 in	 the	 striatum	 is	 also	 sensitive	 in	 differentiating	 vulnerability	
from	disease	manifestation	in	HD	families	from	a	South-American	region	known	
to have high incidence of the disease. In addition, the association of enlarged brain 
perivascular	spaces	(PVS)	with	cognitive,	behavioral,	and	motor	symptoms	of	HD	
is unknown.
Materials and Methods: We have analyzed neuroimaging indicators of global atrophy, 
PVS	burden,	and	GM	tissue	volume	in	the	basal	ganglia	and	thalami,	in	relation	to	be-
havioral, motor, and cognitive scores, in 15 HD patients with overt disease manifesta-
tion	and	14	first-degree	relatives	not	genetically	tested,	which	represent	a	vulnerable	
group,	from	the	region	of	Magdalena,	Colombia.
Results: Poor	fluid	intelligence	as	per	the	Raven's	Standard	Progressive	Matrices	was	
associated with global brain atrophy (p	=	0.002)	and	PVS	burden	 (p ≤ 0.02) in HD 
patients,	where	the	GM	volume	 in	all	subcortical	structures,	with	the	exception	of	
the	right	globus	pallidus,	was	associated	with	motor	or	cognitive	scores.	Only	the	GM	
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1  | INTRODUC TION
Huntington's	disease	 (HD)	 is	 a	neurodegenerative	disorder	caused	
by	 an	 expanded	Cytosine,	Adenine,	 and	Guanine	 (CAG)	 repeat	 on	
chromosome	4	(Ciarmiello	et	al.,	2017).	A	formal	diagnosis	is	made	
when motor symptoms that are typical for HD appear in an indi-
vidual who has a positive family history of the disease confirmed 
by	gene	 testing	 (Tabrizi	 et	 al.,	 2009).	As	 genetic	 tests	 can	be	per-
formed	 on	 individuals	 to	 identify	 if	 they	 have	 the	 expanded	CAG	
repeat, the natural history and pathophysiology of the disease 
can be studied several years before the disease manifests (Tabrizi 
et al., 2013). This makes HD a model neurodegenerative disorder 
to study, which could help understanding other neurodegenerative 
diseases,	which	 cannot	be	diagnosed	years	before	onset	 (Aylward	
et al., 2013). Classically, HD is characterized by a triad of symp-
toms including motor, cognitive, and behavioral abnormalities (Baez 
et al., 2016), and has been associated with neuronal loss within cor-
ticostriatal circuits, reflected in brain structural changes visible in 
magnetic	resonance	imaging	(MRI)	(Georgiou-Karistianis	et	al.,	2013;	
Kim	&	Fung,	2014;	Lawrence,	Sahakian,	&	Robbins,	1998;	McColgan	
& Tabrizi, 2018). The sensitivity of these volumetric changes in rela-
tion to cognitive and social performance, to differentiate manifest 
HD	patients	from	first-degree	relatives	who	represent	a	vulnerable	
group, would benefit from further documentation, especially across 
a wide lifespan trajectory and ethnic groups.
Several studies conducted under the framework of interna-
tional multisite observational projects for the study of HD (e.g., 
TRACK-HD,	COHORT,	PREDICT-HD),	 have	 revealed	many	 clinical	
and biological indicators of disease progression, including neuro-
imaging	parameters	 (Aylward,	2014;	Aylward	et	al.,	2013).	For	ex-
ample, studies have found strong correlations between many gray 
and white matter regions and clinical tests, including recognition of 
negative emotions, metronome tapping precision, and measures of 
tongue	force.	A	study	found	that	the	symbol	digit	modalities	test,	
a	measure	of	processing	speed,	was	correlated	with	annual	whole-
brain volume loss in HD patients (Tabrizi et al., 2011). White matter 
atrophy has been reported in the earliest premanifest stages of HD 
(Aylward	et	al.,	2013;	Tabrizi	et	al.,	2013).	It	has	also	been	noted	that	
atrophy of individual brain structures, specifically in the striatum 
(i.e., accumbens nucleus, caudate nucleus, putamen, and pallidum), 
could	be	a	more	sensitive	biomarker	compared	to	whole-brain	vol-
ume (van den Bogaard et al., 2011, Tabrizi et al., 2011, 2013). For 
example, it has been found that cortical gray matter volume and 
thickness are reduced in premanifest individuals, from 9 to 15 years 
before	the	clinical	onset	of	HD	(Jurgens	et	al.,	2008).	In	these	preon-
set stages, volume losses in striatal structures have been associated 
with	higher	chorea	scores	(Coppen,	Jacobs,	Berg-Huysmans,	Grond,	
&	Roos,	2018;	Jurgens	et	al.,	2008),	smaller	putamen	volume	with	
motor deficits, and atrophy in the caudate has been correlated with 
cognitive decline (Coppen et al., 2018). However, although striatal 
atrophy	is	considered	a	signature	of	the	disease	(Aylward,	2014),	the	
suitability of, specifically, gray matter loss in the striatum to differ-
entiate overt HD from vulnerability, regardless of whether the latter 
are gene carriers or not, would benefit from further analyses involv-
ing individuals across different ethnic groups.
Despite notable efforts to document this disease, most of the in-
formation available has been provided by studies involving individuals 
from	North	America,	Australia,	and	Western	Europe.	It	therefore	seems	
important to validate previous analyses in samples from communities 
geographically distant and ethnically different from those that usu-
ally contribute to data, especially because environmental factors are 
known to modulate motor, cognitive, affective, and other symptoms 
of	HD	 (Mo,	Hannan,	&	Renoir,	2015).	We	attempted	 to	 fill	 this	void	
in the current scientific literature by studying the neuroimaging atro-
phy markers of HD reported by previous studies in a cohort of HD pa-
tients	and	their	first-degree	relatives	from	Magdalena,	Colombia.	This	
Colombian region has a high prevalence of the disease, previously re-
ported as the second largest worldwide (Baez et al., 2015, 2016, 2018; 
Kargieman et al., 2014). Impairments in negative emotion recognition 
and empathy for pain (Baez et al., 2015), reduced Schadenfreude (Baez 
et	al.,	2016),	and	motor-language	coupling	(Kargieman	et	al.,	2014)	have	
been	reported	to	affect	HD	families	in	the	region.	A	study	that	involved	
HD	patients	from	this	region	and	age-matched	unrelated	controls	as-
sociated the ventral striatum, precuneus, and superior parietal lobule 
with Schadenfreude in HD patients (Baez et al., 2018). The atrophy 
patterns reported by Baez and colleagues, which involved the basal 
ganglia and thalamus as well as the frontal and parietal cortex, matched 
previous reports on HD (Baez et al., 2018).
receives	funding	from	the	DRI	Momentum	
Award,	the	DFG	(SFB/TR167	B07),	the	
DZNE and the BIH.
volume	in	the	right	putamen	was	associated	with	envy	and	MOCA	scores	(p = 0.008 
and	0.015	respectively)	in	first-degree	relatives.
Conclusion: Striatal	 GM	 volume,	 global	 brain	 atrophy	 and	 PVS	 burden	may	 serve	
as	 differential	 indicators	 of	 disease	 manifestation	 in	 HD.	 The	 Raven's	 Standard	
Progressive	Matrices	could	be	a	cognitive	test	worth	to	consider	in	the	differentiation	
of vulnerability versus overt disease in HD.
K E Y W O R D S
basal	ganglia,	cognition,	fluid	intelligence,	Huntington’s	Disease,	MRI,	perivascular	spaces,	
Raven matrices
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Moreover,	the	need	for	reliable	markers	of	disease	progression	
remains an area of intense research (Kim & Fung, 2014). Enlarged 
perivascular	 spaces	 (PVS),	 a	 known	 indicator	of	brain	 atrophy	and	
white	matter	pathology	(Wardlaw	et	al.,	2013),	are	pial-lined	intersti-
tial	fluid-filled	spaces	in	the	brain	that	surround	perforating	vessels	
and have been identified a feature of small vessel disease (Wardlaw 
et al., 2013), playing an important role in sleep disorders (Berezuk 
et	al.,	2015).	Traditionally,	PVS	have	been	considered	passive	ana-
tomical structures resultant from transient vasoconstriction and 
vasodilation of the vessels they surround. Their appearance also 
in the absence of any pathology has perhaps contributed to their 
neglect in studies of neurodegenerative diseases. However, recent 
studies have shown they play an active role in cleaning toxic sol-
utes and are a sign of glymphatic fluid stasis, playing a role in the 
pathogenesis	 of	 neurodegenerative	 diseases	 (Mestre,	 Kostrikov,	
Mehta,	 &	Nedergaard,	 2017).	Hence,	 their	 visibility	 and	 size	 have	
been reported to increase with age (Francis, Ballerini, & Wardlaw, 
2019),	 in	 Alzheimer's	 disease	 (Ramirez	 et	 al.,	 2015),	 and	 they	 are	
considered	 highly	 heritable	 (Duperron	 et	 al.,	 2018).	 Although	 the	
presence	of	PVS	in	HD	patients	has	not	been	reported	in	the	scien-
tific	literature	so	far,	neuroradiological	reports	of	PVS	in	HD	patients	
has been a matter of concern for caregivers in one of the internet 
support forums hosted by the HD Lighthouse Families Community 
(http://www.hdlf.org/commu nity). In this study, we evaluate, for the 
first	 time,	whether	PVS	can	be	considered	a	neuroimaging	marker	
that differentiates vulnerability versus overt HD, and their asso-
ciation with cognitive, functional, and behavioral indicators in HD 
patients	 and	 their	 first-degree	 relatives.	We	 hypothesize	 that	 the	
PVS	burden	will	 be	higher	 in	HD	patients	 compared	 to	 their	 first-
degree	relatives.	However,	as	cross-sectional	cognitive	studies	have	
not	found	a	strong	effect	of	total	PVS	burden	on	general	cognition	
(Huijts et al., 2014; Hurford et al., 2014; Zhu et al., 2010), we did not 
expect	an	association	of	PVS	burden	with	functional,	cognitive,	or	
behavioral symptoms of HD.
2  | MATERIAL S AND METHODS
2.1 | Subjects
This	 study	 included	29	 individuals	 from	 the	 region	of	Magdalena,	
Colombia:	15	patients	and	14	first-degree	relatives.	The	HD	patients	
were diagnosed both genetically and clinically with the disease, and 
the	first-degree	relatives	were	either	descendants	or	siblings	of	the	
patients. Individuals in this family group were not diagnosed with 
HD	 when	 the	 study	 was	 conducted.	 Although	 relatives	 did	 not	
receive genetic testing, this population represents a vulnerabil-
ity	 group.	 Biological	 (Markianos,	 Panas,	 Kalfakis,	&	Vassilopoulos,	
2008), clinical (Dorsey, 2012), and cognitive (Baez et al., 2015; 
Giordani et al., 1995; Kargieman et al., 2014) factors of familial vul-
nerability	have	been	reported	irrespective	of	whether	the	first-de-
gree	relatives	are	HD	mutation	carriers	or	not.	Vulnerability	to	HD	
means that individuals with a family history of the disease have a 
high probability of developing it or some unspecific deficits related 
to	it.	Assessing	these	individuals	is	important	to	understand	the	na-
ture of HD and identify potential HD biomarkers (Baez et al., 2015, 
2016; Kargieman et al., 2014).
Both	 groups	 were	 assessed	 using	 the	 Unified	 Huntington's	
Disease	 Rating	 Scale	 (UHDRS)	 (Siesling,	 Vugt,	 Zwinderman,	
Kieburtz, & Roos, 1998). The mean UHDRS score reported for pa-
tients was 20.5 (SD 8.6), and for relatives it was 0.2 (SD 0.4) (Baez 
et al., 2015). In addition, HD patients were assessed with the Total 
Functional Capacity Scale (HDFCS) (Shoulson & Fahn, 1979). The 
mean HDFCS score reported was 11.8 (SD 1.5) (Baez et al., 2015). 
Thirteen patients (87%) did not receive any pharmacologic treat-
ment. Two patients (13%) were taking antidepressants, antipsy-
chotics, or/and Tetrabenzine. Patients and relatives had no history 
of other major neurological illness, psychiatric disorders, or alcohol/
drug	 abuse.	 All	 participants	 completed	written	 informed	 consent,	
and the ethics committee of the Institute of Cognitive Neurology 
and	the	Autonomous	Caribbean	University	approved	the	study	(res-
olution	59-A)	and	the	use	of	 the	data	 for	 research	purposes	 (Baez	 
et al., 2016).
2.2 | MRI acquisition
The	brain	MRI	scans	were	obtained	from	a	1.5T	Siemens	Magnetom	
scanner	 equipped	 with	 a	 standard	 head	 coil,	 and	 were	 made	
available for this study after a full anonymization using Dicom 
Confidential (https ://sourc eforge.net/proje cts/priva cygua rd/), an 
open-source	java	DICOM	de-identification	tool.	This	study	analyzed	
the	T1-weighted,	Fluid	Attenuated	Inversion	Recovery	(FLAIR),	and	
T2-weighted	MRI.	The	3D	T1-weighted	(gradient	echo	inversion	re-
covery)	 sequence	 had	 TR/TE/TI	 =	 2070/5.18/1100	ms,	 flip	 angle	
15o,	voxel	size	[0.9375,	0.9375,	1],	acquisition	matrix	256x256x176.	
The	T2-weighted	(spin	echo)	sequence	was	acquired	in	axial	orienta-
tion, with TR/TE = 4,860/110 ms, slice thickness 5mm, voxel size 
[0.4492,	 0.4492,	 6.5],	 acquisition	 matrix	 418x512x20.	 The	 FLAIR	
(spin	 echo	 inversion	 recovery)	 sequence	was	 also	 acquired	 axially,	
with TR/TE/TI = 11,000/140/2500 ms, voxel size [0.8984, 0.8984, 
6.5],	acquisition	matrix	232	×	256	×	20.
2.3 | Image analysis
2.3.1 | Volumetric measurements
Contents	of	intracranial	volume	(ICV)	within	the	inner	skull	table	in-
cluding normal appearing white matter, cerebrospinal fluid, brain tis-
sue, veins and dura, were initially extracted automatically using the 
brain	extraction	tool	(BET2)	from	the	FMRIB	software	library	(FSL)	
(https	://fsl.fmrib.ox.ac.uk/fsl/fslwiki).	 Binary	 ICV	masks	were	 visu-
ally checked and manually edited in axial, coronal, and sagittal planes 
when	required	using	Mango	(http://ric.uthsc	sa.edu/mango/	).	Normal	
appearing	white	matter	(NAWM)	and	cerebrospinal	fluid	(CSF)	were	
also segmented using another tool from the same library: the FSL au-
tomatic	segmentation	tool	(FAST).	The	structures	of	the	basal	ganglia	
and thalami were extracted using a combination of other three tools 
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also	from	the	same	library:	Smallest	Univalue	Segment	Assimilating	
Nucleus	 (SUSAN),	 FMRIB's	 Linear	 Image	 Registration	 Tool	 (FLIRT)	
and	a	model-based	segmentation/registration	tool	(FIRST),	combined	
in	an	automatic	pipeline	developed	 in-house	 (Valdés	Hernández	et	
al., 2015). The probabilistic maps resultant from the tissue extraction 
was combined with the results from the subcortical segmentations 
to	discern	the	volume	of	gray	matter	(GM)	tissue	in	the	striatal	struc-
tures. These results were visually assessed for further manual editing 
when	it	was	required.	In	addition,	for	compatibility	with	other	studies	
that had calculated the full volume of the subcortical structures, the 
latter were also calculated. Figure S1 in the Supplementary material 
illustrates	the	differences	between	the	GM	tissue	(i.e.,	volumes	ana-
lyzed here) and the boundaries of the whole right and left putamen 
structures in one study participant.
PVs	 were	 segmented	 automatically	 using	 a	 MATLAB	 Graphic	
Unit	Interface	“Extracting_small_T2W_hyperintensities,”	part	of	the	
library	of	MATLAB	tools	bric1936	freely	available	from	https	://sourc	
eforge.net/proje	cts/bric1	936/files/	MATLAB_R2015a_to_R2017	b/.	
This	GUI	performs	an	adaptive	histogram	equalization	 to	enhance	
the	 contrast	 between	 hyper-/hypo-intensities	 and	 background,	
to	 automatically	 extract	 signal-enhanced	 features	 from	 the	 back-
ground or tissue. It also uses connected component analysis to con-
straint the size of these features and describe their properties. This 
GUI also allows to manually remove false positives and to change the 
sensitivity of the detection algorithm. Finally, it outputs volume and 
count	of	each	structure	 identified	per	slice.	Total	PVS	volume	and	
count were used in our analyses.
All	brain	volumes	were	adjusted	for	head	size	related	differences	
using	 ICV.	 All	 measurements	 were	 performed	 blind	 to	 any	 other	
clinical, cognitive, or demographic information. Three observers 
of	different	levels	of	experience	(JA,	XQ,	and	MVH)	assessed	each	
segmentation result, and discrepancies were discussed until a final 
agreement was reached.
2.3.2 | Visual PVS rating
Despite	 recent	 computational	 methods	 for	 assessing	 PVS	 have	
shown promising for being applied in clinical research and practice 
(Ballerini	et	al.,	2018),	still	 the	gold-standard	method	for	assessing	
PVS	is	neuroradiological	(i.e.,	visual)	rating.	A	trained	observer	(XQ)	
rated	 the	 PVS	 using	 the	 Potter	 scale	 (Potter,	 Chappell,	Morris,	 &	
Wardlaw,	2015).	Briefly,	this	scale	rates	the	PVS	separately	in	three	
major anatomical brain regions: midbrain, basal ganglia and centrum 
semiovale,	in	T2-weighted	axial	slices	representative	of	the	PVS	bur-
den in each region. The rating is done separately for left and right 
hemispheres, but a combined score that represents the average of 
the	PVS	burden	in	each	region	is	given.	The	rating	can	be	0	(no	PVS),	
1	 (mild;	 1–10	 PVS),	 2	 (moderate;	 11–20	 PVS),	 3	 (frequent;	 21–40	
PVS),	or	4	(severe;	>40	PVS)	(Potter	et	al.,	2015).	Ratings	were	done	
twice by the same rater, blind to any clinical, demographic, or cogni-
tive	information,	and	to	the	previous	scores.	Where	intra-observer	
differences were observed, the final score was decided on a team 
discussion of each case, also blind to any other information.
2.4 | Functional assessments
The	Myer's	functional	score	was	used	to	assess	the	level	of	disability.	
This score ranges from 100 to 10, with a score of 10 indicating high 
levels	of	disability.	This	physical	disability	score	has	a	high	inter-rater	
reliability	(Myers	et	al.,	1991).
2.5 | Cognitive assessments
The	general	cognitive	status	was	assessed	with	the	Montreal	Cognitive	
Assessment	 (MOCA).	MOCA	 is	 a	 very	 sensitive	 cognitive	 screening	
tool	that	covers	important	cognitive	domains	such	as	short-term	mem-
ory, working memory, language, and orientation (Nasreddine et al., 
2005). To assess executive function, the INECO frontal screening (IFS) 
test was used. It includes eight subtests; motor programming, conflict-
ing instructions, motor inhibitory control, numerical working memory, 
verbal working memory, spatial working memory, abstraction capac-
ity, and verbal inhibitory control (Torralva, Roca, Gleichgerrcht, Lopez, 
&	Manes,	 2009).	 To	 assess	 fluid	 intelligence,	 the	 Raven's	 Standard	
Progressive	Matrices	were	used.	This	60-item	test	assesses	fluid	intel-
ligence nonverbally, and is often included in research on patients with 
cognitive deficits, however, has only rarely been used in patients with 
HD (Bilker et al., 2012).
2.6 | Socio‐emotional assessments
A	social	cognition	test	 indexing	social	emotions	was	performed	by	
all	 study	participants.	 In	 it,	 each	participant	was	 shown	 a	 real-life	
photograph and a description of two characters matched in age and 
gender with the participant.
The	test	comprised	two	experimental	blocks	(i.e.,	parts	A	and	B),	
and it was performed using a battery administered by the Data Host 
Institution	in	Colombia.	Part	A	investigated	envy	ratings.	In	it,	partic-
ipants read eight sentences describing four fortunate events involv-
ing	each	character.	After	reading	each	sentence,	participants	rated	
the event in terms of how much envy they felt for the character 
(1 = no envy, 9 = extreme envy). Part B calculated the Schadenfreude 
ratings. In it, participants read and reported the intensity of their 
pleasure (i.e., schadenfreude: 1 = no pleasure, 9 = extreme pleasure) 
in response to eight unfortunate events (e.g., cuckoldry caused by 
the	 character's	 girlfriend/boyfriend)	 happening	 to	 the	 characters	
(i.e., also four events per character). Two neutral events (e.g., washing 
clothes) were included in each experimental block. Events were pre-
sented	 in	pseudo-randomized	order.	These	socio-emotional	scores	
have been previously validated in HD (Baez et al., 2016, 2018).
2.7 | Statistical analyses
All	brain	volume	variables	were	standardized	by	ICV	and	expressed	as	
percentage	of	it.	Statistical	analyses	were	performed	using	IBM	SPSS	
Statistics 21.0.0. The sample was divided into two groups: the “patient 
group”	and	the	“family	group,”	the	latter	grouping	the	first-degree	rela-
tives.	As	one	of	our	main	goals	was	to	investigate	whether	the	imaging	
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markers analyzed were sensitive enough to be considered neuroim-
aging markers that differentiate vulnerability from disease manifes-
tation in HD families, both study groups were assessed separately 
in	 cross-correlation	 analyses	 and	 linear	 regression	models.	 Bivariate	
cross-correlations	were	performed	with	bootstrap.	Age,	sex,	and	years	
of education were used as covariates in the univariate linear regres-
sion models to control for any confounding effects these variables may 
have. In these models, our dependent variable was either the func-
tional,	cognitive,	or	socio-emotional	score	and	the	independent	vari-
able was the brain volumetric (or score) variable. Bootstrap was also 
used	in	linear	regression	models,	which	were	double-checked	against	
general	linear	models.	Both	groups	were	compared	using	the	Median	
and	Mann-Whitney	U	tests	to	find	parameters	that	differ	significantly	
between them.
3  | RESULTS
3.1 | Sample characteristics
The descriptive characteristics of the imaging and cognitive vari-
ables involved in the analyses are given in Table 1. The mean age 
of the total sample was 36.76 years (HD patients: 45.87, standard 
deviation (SD) 9.42 years old and family: 27 (SD 7.89) years old). The 
descriptive statistics of each sex subgroup for relatives and patients 
appears in the Table S1. On average, female participants had one 
year more of education than males in the patient group and the op-
posite pattern in the family group. The group of HD patients (n = 15, 
eight female) was on average approximately 20 years older and had 
3 fewer years of education than the family group (n = 14, 11 female). 
TA B L E  1   Descriptive statistics of the variables involved in the analyses
 
Descriptive statistics
Group comparison 
(p‐values)
Total (mean ± SD)
HD Patients (n = 15) 
(mean ± SD or median (IQR))
First‐Degree Relatives (n = 14) 
(mean ± SD or median (IQR)) Median test
Mann‐
Whitney 
U test
Demographic	Variables	(years)
Age 45.87 ± 9.42 26.38 ± 7.86 0.001 0.007 36.76 ± 12.86
Education 9.20 ± 3.19 12.77 ± 2.17 0.001 0.001 10.97 ± 3.26
Imaging	Volumetric	Variables	(%	in	ICV)
NAWM 35.70 ± 1.67 38.063 ± 1.63 0.13 0.0040 36.80 ± 2.017
CSF 28.30 ± 3.11 19.67 ± 2.38 <0.0001 <0.0001 24.29 ± 5.17
Left caudate nucleus 0.11 ± 0.041 0.20 ± 0.037 <0.0001 <0.0001 0.15 ± 0.061
Right caudate nucleus 0.094 ± 0.060 0.21 ± 0.037 <0.0001 <0.0001 0.15 ± 0.078
Left putamen 0.075 ± 0.028 0.14 ± 0.035 <0.0001 <0.0001 0.11 ± 0.046
Right putamen 0.071 ± 0.024 0.16 ± 0.038 <0.0001 <0.0001 0.11 ± 0.053
Left globus pallidus 0.0066 ± 0.0053 0.0070 ± 0.0037 1.00 0.62 0.0068 ± 0.0041
Right globus pallidus 0.0052 ± 0.0033 0.0075 ± 0.0047 1.00 0.29 0.0063 ± 0.0041
Left thalamus 0.16 ± 0.029 0.21 ± 0.032 0.0020 <0.0001 0.18 ± 0.040
Right thalamus 0.17 ± 0.023 0.22 ± 0.025 0.0020 <0.0001 0.19 ± 0.036
BGPVS 0.030 ± 0.017 0.021 ± 0.0084 0.45 0.16 0.026 ± 0.015
PVS	visual	scores	(Potter	scale)	[median	(IQR)]
Basal	GANGLIA 1 (1) 1 (0) 0.0070 0.037 1 (1)
Centrum	SEMIOVALE 2 (1) 1 (1) 0.14 0.12 1 (1)
Midbrain 0 (1) 0 (1) 0.71 0.68 0 (1)
Functional,	Cognitive	and	Socio-emotional	Assessment	Scores	(arbitrary	units)
Myer's	Functional	
Score
76.77 ± 14.47 99.23 ± 2.77 — <0.0001 87.59 ± 15.51
IFS_Total 14.53 ± 5.90 22.23 ± 2.95 0.0030 <0.0001 18.17 ± 6.00
MOCA_Total 17.07 ± 4.68 26.15 ± 2.85 <0.0001 <0.0001 21.24 ± 5.92
Raven	Matrices 4.67 ± 4.22 12.08 ± 6.59 0.0090 0.001 7.97 ± 6.46
Soc.Emot.	Part	A	Total 30.67 ± 20.15 36.77 ± 16.92 0.72 0.19 34.41 ± 18.95
Soc Emot. Part B Total 44.40 ± 19.26 23.38 ± 12.66 0.0080 0.0010 33.90 ± 19.50
Note: PVS	visual	scores	values	are	median	and	interquartile	range	(nonparametric	ordinal	variables).
Abbreviations:	NAWM:	normal	appearing	white	matter;	CSF:	cerebrospinal	fluid;	BGPVS:	basal	ganglia	perivascular	spaces.
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Age	 and	 years	 of	 education	 significantly	 differed	 between	 family	
and patient groups.
3.2 | Group comparison
The	 significance	 values	 obtained	 from	 the	 Median	 and	 Mann–
Whitney U tests are shown in Table 1. Figures 1 and 2 illustrate the 
magnitudes of the brain volumetric measurements and the func-
tional,	 cognitive	 and	 socio-emotional	 tests	 scores	 respectively,	 in	
each	group.	The	median	values	of	NAWM,	left,	and	right	GM	in	the	
globus	pallidus	and	basal	ganglia	PVS	volumes,	were	not	significantly	
different between the family and patient groups. The median and dis-
tribution of the rest of the volumetric variables and the visual score 
of	PVS	burden	 in	 the	 basal	 ganglia	 differed	between	both	 groups	
(See	Table	1).	The	Myer's	functional	score	differed	between	family	
and patient groups (p < 0.0001). The scores from the three cogni-
tive tests were significantly different between groups (p < 0.001). 
The	 scores	 from	 the	 socio-emotional	 test	 part	 B	 (Schadenfreude)	
differed between groups (p	<	0.001),	but	not	those	from	the	part	A	
(envy) (p	>	0.15).
3.3 | Bivariate relations in each group
Table 2 shows the nonparametric bootstrapped bivariate relations of 
the	functional,	cognitive,	and	socio-emotional	tests	results	with	the	
neuroimaging assessments (volumetric, adjusted by head size, and 
visual ratings), for the imaging variables that were correlated with 
at	least	one	of	the	functional,	cognitive,	or	socio-emotional	scores,	
in	 each	 group.	 Parametric	 (Pearson's)	 correlations	 yielded	 similar	
results.
F I G U R E  1   Illustration	of	the	magnitude	of	the	volumetric	measurements	per	group.	(a)	Global	atrophy-related	measurements	and	(b)	gray	
matter volume in the subcortical structures analyzed. Significance was determined without adjusting for any demographic variable (i.e., age, 
biological sex)
F I G U R E  2   Illustration of the magnitude of the cognitive, motor, and behavioral scores per group. Significance was determined without 
adjusting for any demographic variable (i.e., age, biological sex)
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3.3.1 | Correlations between the imaging 
variables and the functional score
The	Myer's	functional	scores	were	only	correlated	with	variables	in	
the	patient	group	but	not	 in	the	family	group.	 In	patients,	 the	GM	
volumes of the left caudate, left and right putamen, right globus pal-
lidus,	and	general	brain	atrophy	correlated	with	 the	Myer's	 scores	
(p < 0.05). However, the only variable that had a strong and signifi-
cant correlation (Spearman ρ	=	−0.662,	p = 0.007) with the functional 
scores	was	the	PVS	visual	score	in	the	basal	ganglia.	The	PVS	scores	
in	the	centrum	semiovale	correlated	with	the	Myer's	tests	scores	at	
the p < 0.05 significance level only in the patient group (Spearman 
ρ	=	−0.605,	p = 0.017).
3.3.2 | Correlations between the imaging 
variables and the cognitive scores
The	 outcome	 from	 the	 INECO	 frontal	 screening	 and	MOCA	 tests	
correlated	with	 the	 left/right	caudate	and	 right	putaminal	GM	tis-
sue volumes only in the patient group (p	<	0.05).	The	volume	of	GM	
tissue in the left caudate was correlated with the Raven matrices 
results only in the family group (p < 0.05).
3.3.3 | Correlations between the imaging 
variables and the socio‐emotional test scores
The	outcome	from	the	socio-emotional	test	part	A	(i.e.,	envy	ratings)	
correlated	strongly	and	significantly	with	the	volume	of	the	GM	tis-
sue in the left thalamus of patients (Spearman ρ = 0.748, p = 0.001) 
but	not	in	first-degree	relatives.	The	outcome	from	the	socio-emo-
tional test part B (i.e., Schadenfreude ratings) correlated with the 
PVS	scores	in	the	centrum	semiovale	in	the	family	group	(i.e.,	not	in	
patients) at the p < 0.05 level of significance (Spearman ρ	=	−0.606,	
p = 0.028).
3.4 | Associations in each group
Table 3 shows the values of the nonstandardized coefficients, stand-
ard errors, and significances in the linear regression models.
3.4.1 | Associations between the imaging 
variables and the functional scores
The	Myer's	functional	scores	were	only	associated	with	imaging	pa-
rameters in the patient group, but not in the family group. From the 
imaging variables that were correlated with the functional score, 
only	the	volume	of	the	GM	tissue	(i.e.,	excluding	white	matter	and	
vascular	 abnormalities)	 in	 the	 right	 globus	 pallidus	 and	 the	 PVS	
score in the centrum semiovale were not associated with the func-
tional score after correcting for age, biological sex, and years of ed-
ucation. Of note, the significance in the associations that held (i.e., 
with	global	atrophy,	left	caudate,	right/left	putamen	GM	volumes,	
and	basal	ganglia	PVS	scores),	the	level	of	significance	was	p < 0.05.
3.4.2 | Associations between the imaging 
variables and the cognitive scores
Accounting	 for	 age,	 biological	 sex,	 and	 years	 of	 education	 changed	
the pattern of bivariate correlations between imaging and cognitive 
variables. Only in the patient group (and not in the family group), the 
outcome of the cognitive tests was associated with some of the imag-
ing variables analyzed. Fluid intelligence (i.e., from Raven matrices) was 
associated with global atrophy (β	=	−6.84,	p = 0.002), left putaminal 
GM	tissue	volume	(β = 0.600, p	=	0.034),	GM	tissue	volume	in	the	left	
thalamus (β = 0.592, p	=	0.040),	and	PVS	scores	in	all	regions:	basal	gan-
glia (β=−0.471,	p = 0.022), centrum semiovale (β	=	−0.578,	p = 0.015), 
and midbrain (β	=	−0.489,	p = 0.020). The INECO frontal screening and 
MOCA	scores	only	were	associated	with	the	right	caudate	GM	tissue	
volume in patients (β = 0.662, p = 0.039 and β = 0.684, p = 0.037 re-
spectively).	MOCA	 scores	were	 associated	with	 the	 right	 putaminal	
GM	tissue	volume	in	the	family	group	(β	=	−0.948,	p = 0.015).
3.4.3 | Associations between the imaging 
variables and the socio‐emotional scores
Only	the	socio-emotional	test	part	A	(i.e.,	envy	ratings)	was	associ-
ated with imaging variables after controlling for age, biological sex, 
and years of education. In the patient group, it was associated with 
the	GM	tissue	volume	in	the	left	thalamus	(β = 0.825, p = 0.011), and 
in	the	family	group	it	was	associated	with	the	volume	of	total	NAWM	
(β	=	−0.618,	p	=	0.036),	and	with	the	GM	tissue	volume	in	the	right	
putamen (β = 0.829, p = 0.008).
3.5 | Comparability with published outcomes
Volumetric	 differences	 between	 the	 conventionally	 reported	 sub-
cortical	volumes	and	the	volumes	of	the	GM	tissue	in	these	struc-
tures (i.e., measurements analyzed and reported in this study) exist. 
As	Figure	S2	and	Table	S2	show,	subcortical	volumes	were,	on	av-
erage	20%	bigger	 (confidence	 interval	also	20%)	than	the	GM	vol-
ume in these structures, and these differences were slightly higher 
in	higher	volumes.	After	adjusting	for	intracranial	volume	(i.e.,	head	
size), the differences between these measurements were 1% smaller 
on average. The globus pallidus was, however, generally two times 
bigger	than	the	GM	volume	in	this	structure.
4  | DISCUSSION
4.1 | Main findings
In	 line	 with	 our	 main	 hypotheses,	 the	 GM	 volume	 in	 the	 basal	
ganglia and thalami resulted a sensitive differential indicator of 
disease manifestation versus vulnerability in HD families from a 
South-American	region	known	to	have	high	 incidence	of	the	dis-
ease.	In	addition,	we	examined	for	the	first	time	the	PVS	burden	
in	HD	patients	compared	to	first-degree	relatives,	and	found	that	
the	 PVS	 burden	 was	 predictive	 of	 reduced	 fluid	 intelligence	 in	
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HD patients only, and not in the vulnerable group, opening a new 
area	of	research.	As	result	of	our	analyses,	from	all	cognitive	and	
socio-emotional	 tests	 applied,	 the	 Raven's	 Standard	 Progressive	
Matrices	exhibited	the	greatest	discriminatory	power	for	overt	HD	
versus vulnerability to the disease after adjusting for age, biologi-
cal sex, and years of education; thus suggesting its usefulness in 
the study of this disease.
Our	 finding	 that	 whole-brain	 atrophy	 (i.e.,	 for	 which	 CSF	
volume is a surrogate measure) was associated with poorer per-
formance in the Raven test in HD patients, is in agreement with 
previous	studies	that	have	also	found	whole-brain	volume	loss	to	
be associated with cognitive measures in HD patients (Tabrizi et 
al.,	2011).	Whole-brain	atrophy	is	not	just	present	in	manifest	HD	
stages, but also in premanifest stages, as it can appear as much as 
10 years before predicted onset (Tabrizi et al., 2009). The fact that 
both	 the	 left	 and	 right	 putaminal	 GM	 volumes	 were	 associated	
with Raven test results in HD patients is in line with a previous 
study	by	Jurgens	et	al.	 (2008)	who	found	a	 link	between	smaller	
putamen volume and cognition in patients with premanifest HD, 
specifically	in	the	Trail	Making	Test	B	and	symbol	digit	modalities	
tests,	although	did	not	consider	any	confounding	factor.	Aylward	
et al. (2013) also observed that structures in the basal ganglia 
contributed more than other brain regions to the prediction of 
cognitive	 performance	 in	 individuals	with	 prodromal	HD.	Cross-
sectional studies have found that reductions in putaminal volume 
can appear up to 15–20 years before disease onset in carriers of 
the	mutant	allele	(Scahill,	Andre,	Tabrizi,	&	Aylward,	2017).	The	as-
sociation we observed between the Raven matrices scores and the 
GM	volumes	of	the	left	thalamus	in	HD	patients	has	not	been	pre-
viously	reported.	Kassubek,	Juengling,	Ecker,	and	Landwehrmeyer	
(2005) found correlations between thalamic volume and cognition 
in individuals with HD. They reported that the thalamic subnuclei 
projecting to prefrontal areas and connected to the striatum par-
ticularly displayed volume loss. Recent studies suggested that the 
thalamus only shows significant atrophy in the later stages of HD 
(Hobbs et al., 2010; Scahill et al., 2017). Thus, the negative asso-
ciation	between	fluid	intelligence	and	PVS	burden	we	observed	in	
HD patients warrants further research.
The	socio-emotional	test	part	A	was	also	associated	with	the	
GM	volume	in	the	left	thalamus	in	HD	patients	but	not	in	the	vul-
nerable	group.	The	effects	of	thalamic	GM	volume	on	socio-emo-
tional cognition in HD have not been investigated. This is surprising 
as the thalamus is part of the limbic system, which is largely known 
for its associations with emotion processing (Wilkos, Brown, 
Slawinska, & Kucharska, 2015). The important role of the thala-
mus in the brain network involved in emotion processing has been 
highlighted	by	 several	 studies	 (Pessoa,	2017).	A	 study	on	neural	
correlates of jealousy identified the thalamus as one of the struc-
tures involved (Sun et al., 2015). It has been proposed that the 
neural correlate of envy involves the thalamus in the process of 
response to emotions, which are projected to the insula, and then 
into the orbitofrontal and anterior cingulate regions of the fron-
tal	 lobe	 (Kong,	 2010).	Moreover,	 associations	 between	 thalamic	
volume	 and	 socio-emotional	 cognition	 have	 been	 reported	 in	
stroke patients with thalamic lesions from a stroke (Liebermann 
et al., 2013). The thalamus and basal ganglia are part of parallel 
segregated circuits with cortical areas such as the dorsolateral 
prefrontal cortex, the lateral orbitofrontal cortex, and the ante-
rior cingulate/medial orbitofrontal cortices (Bonelli & Cummings, 
2007). These three regions contribute not only to emotion regula-
tion	but	also	to	planning	working	memory,	rule-based	learning	and	
attention (Bonelli & Cummings, 2007). This may explain why we 
found	that	the	GM	volume	of	the	left	thalamus	and	putamen	were	
associated with certain aspects of cognition, tested by the Raven 
matrices	 test	 and	 the	 socio-emotional	 test	 part	A,	 as	 atrophy	 in	
these regions surely affects the circuits that control cognitive, be-
havioral and emotional functions (Cheung et al., 2006).
The caudate is part of the dorsolateral prefrontal cortex cir-
cuit,	which	plays	a	part	in	modulating	the	cognitive-control	process	
and suppresses unwanted behavior, which is essential for cognitive 
control	 (Aylward	 et	 al.,	 2013;	Misiura	 et	 al.,	 2017).	We	 therefore	
expected	associations	between	caudate	GM	volumes	and	the	out-
come	of	the	IFS	and	MOCA	tests	in	the	patient	group.	Several	other	
studies	have	found	similar	associations.	For	example,	Misiura	et	al.	
(2017) found that performances on the symbol digit modalities test, 
an	 emotion	 recognition	 test,	 and	 a	 task	 requiring	 internal	 timing,	
were associated with caudate volume in premanifest HD. It has also 
been	found	that	the	Mini	Mental	State	Examination	(MMSE)	scores	
correlate with caudate volume in the early stages of HD (Niccolini & 
Politis, 2014).
The group comparison of all cognitive and brain volumetric 
variables obtained in our study revealed significant differences be-
tween the groups, with the exception of the globus pallidus and the 
socio-emotional	 cognitive	 test	 part	A.	 The	 pallidum	has	 been	 less	
well investigated in HD compared to other brain structures (van den 
Bogaard et al., 2011). However, Rosas et al. (2003) observed signifi-
cant volume reductions in the pallidum in individuals in the early to 
mid-stages	of	HD.	As	for	the	socio-emotional	cognitive	test	part	A,	
a previous study found that the brain region involved in the feeling 
of envy is preserved in HD patients (Baez et al., 2016), which may 
explain the negative findings in our study. Interestingly, we observed 
that female participants in the patient group and all members of 
the	family	group	had	similar	scores	in	this	test.	A	voxel-based	mor-
phometry	(VBM)	study	identified	the	gray	matter	in	the	dorsolateral	
prefrontal cortex and superior temporal gyrus as the brain regions 
specifically	related	with	dispositional	(i.e.,	not	episodic)	envy	(Xiang	
et	al.,	2017).	Another	VBM	study	 in	patients	with	behavioral	vari-
ant	frontotemporal	dementia	and	patients	with	Alzheimer's	disease	
reported envy to be associated with the anterior cingulate cortex 
(Santamaría-García	et	al.,	2017).	Liu,	Zubieta,	and	Heitzeg	(2012)	ob-
served sex differences in these areas that might partly explain the 
differences	in	the	results	of	the	socio-emotional	cognitive	test	part	
A	in	our	study.
Interestingly,	 although	 the	PVS	count	and	volume	 in	 the	basal	
ganglia adjusted by head size did not differ significantly between 
family and patient groups, the visual scores in this region were 
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significantly	higher	in	patients	compared	with	first-degree	relatives.	
A	previous	analysis	of	computational	versus	visual	neuroradiological	
assessments	of	PVS	concluded	that	while	computational	measure-
ments are least susceptible to be influenced by the overall burden 
of	pathology	in	the	MRI	scan,	neuroradiological	scores	capture	bet-
ter	the	full	flavor	of	pathological	versus	normal	features	(Gonzalez-
Castro	et	al.,	2017).	Contrary	to	our	hypothesis,	PVS	visual	ratings	
in all regions were negatively associated with fluid intelligence in 
the patient group. Studies in nondemented individuals have not as-
certained	an	association	between	PVS	and	cognition	 (Huijts	et	al.,	
2014; Hurford et al., 2014; Zhu et al., 2010). Therefore, the lack of 
association	of	the	PVS	burden	in	the	family	group	is	in	line	with	pre-
vious findings. Our study is the first to explore the putative role and 
prevalence	of	PVS	in	HD,	and	our	result	needs	to	be	confirmed	in	
larger cohorts prior to deriving any conclusions. It is known that mu-
tant Huntingtin forms aggregates that interact with other proteins 
in neurons causing cell dysfunction by different mechanisms, such 
as caspase activation, mitochondrial dysfunction, and increased 
sensitivity	 to	 excitotoxicity	 (Pidgeon	 &	 Rickards,	 2013).	 PVS	 not	
only contain interstitial and cerebrospinal fluids but they also have 
a constant flux of macrophages, which are white blood cell of the 
immune system, and contain vasoactive neuropeptides. The latter, 
in addition to regulating blood pressure and heart rate, have an inte-
gral role in controlling microglia. Some of the mechanisms that cause 
cell dysfunction, and which are triggered by mutant Huntingtin may 
cause neuroinflammation. Interestingly, it has been described that 
perivascular macrophages tend to accumulate during neuroinflam-
mation	and	cause	dilation	of	the	PVS	(Pantoni,	2010).
4.2 | Strengths and weaknesses
To the best of our knowledge, this is the first study to investigate 
correlates between performance on the Raven matrices test with 
neuroimaging	markers	 in	HD.	Although	 the	Raven	 test	 provides	 a	
nonverbal estimate of fluid intelligence and is often included in re-
search on patients with cognitive deficits (Bilker et al., 2012), fluid 
intelligence is not a cognitive parameter usually considered in HD. 
The use of brain structural measures in clinical trials depends on 
having established an association with a clinically meaningful meas-
ure of the disease progression (Tabrizi et al., 2011). Our results will 
hopefully motivate further studies of the Raven matrices test as a 
potential	cognitive	marker	for	HD.	Another	strength	of	our	study	is	
that	it	examines	a	South	American	population	of	a	region	with	high	
incidence of HD. It is important to research the disease in different 
ethnic groups as HD is a genetic disease, which varies in incidence 
across the world, and differences in genetic background and demo-
graphics could account for variations in disease prevalence between 
populations over time (Kay, Hayden, & Leavitt, 2017). The image 
processing and analysis can be considered another strength of this 
study.	Analyzing	and	segmenting	the	MRI	scans	was	done	automati-
cally,	and	results	were	double-checked	afterwards	and	edited	if	nec-
essary	to	ensure	correctness.	All	measurements	were	done	blind	to	
any other information in order to reduce the risk of observer bias.
A	weakness	of	our	study	was	the	lack	of	information	regard-
ing the time from onset of the symptoms in the patient group. 
This affects the analyses of the results, as patients in the man-
ifest stage of the disease often perform worse on cognitive 
tests and some cognitive tests are susceptible to floor effects 
(Ruocco,	Bonilha,	 Li,	 Lopes-Cendes,	&	Cendes,	 2008).	Another	
limitation of the study is the absence of genetic information 
from the first degree relatives. Given our relatively small sample 
size	 and	 the	 ethnic-geographical	 characteristics	 of	 our	 cohort	
(i.e.,	 from	a	specific	 rural	 region	 in	a	South	American	country),	
it would be speculative to conclude on the influence of the ge-
netic data in the associations found. Our focus is to evaluate 
familial vulnerability versus overt disease, adding information 
to	 the	 already	 known	biological	 (Markianos	 et	 al.,	 2008),	 clini-
cal (Dorsey, 2012) and cognitive (Baez et al., 2015; Giordani et 
al., 1995; Kargieman et al., 2014) factors that differentiate both 
groups.	Recent	findings	of	region-specific	atrophies	in	subcorti-
cal structures in premanifest HD underscore the validity of our 
neuroimaging findings (Tang et al., 2019).
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